195 related articles for article (PubMed ID: 29735454)
1. [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].
Zhuang JM; Sun XY; Zhou X; Liu ZQ; Sun J
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Apr; 38(4):496-501. PubMed ID: 29735454
[TBL] [Abstract][Full Text] [Related]
2. [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].
Qiu SQ; Zhuang JM; Zhou X; Yin RX; Liu ZQ; Ma F; Li YJ; Sun J
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Oct; 37(10):1391-1395. PubMed ID: 29070472
[TBL] [Abstract][Full Text] [Related]
3. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
[TBL] [Abstract][Full Text] [Related]
4. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
[TBL] [Abstract][Full Text] [Related]
6. Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A.
Agosti P; Siboni SM; Scardo S; Torri A; Gualtierotti R; Peyvandi F
Blood Adv; 2023 Dec; 7(23):7209-7215. PubMed ID: 37871302
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.
Yao W; Xiao J; Cheng X; Feng G; Li C; Zhang X; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Zhao Y; Wu R
Clin Appl Thromb Hemost; 2017 Oct; 23(7):851-858. PubMed ID: 27920236
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of individualized primary prophylactic treatment of 19 cases of children with severe hemophilia A].
Liu GQ; Tang L; Wu XY; Zhen YZ; Li G; Chen ZP; Wang Y; Zhang NN; Zhang JS; Yu GX; Wu RH
Zhonghua Er Ke Za Zhi; 2016 Dec; 54(12):923-926. PubMed ID: 27938593
[No Abstract] [Full Text] [Related]
10. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
Feldman BM; Pai M; Rivard GE; Israels S; Poon MC; Demers C; Robinson S; Luke KH; Wu JK; Gill K; Lillicrap D; Babyn P; McLimont M; Blanchette VS;
J Thromb Haemost; 2006 Jun; 4(6):1228-36. PubMed ID: 16706965
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients.
Arvanitakis A; Jepsen C; Andersson NG; Baghaei F; Astermark J
Haemophilia; 2024 May; 30(3):671-677. PubMed ID: 38575549
[TBL] [Abstract][Full Text] [Related]
12. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
[TBL] [Abstract][Full Text] [Related]
13. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
Collins PW; Blanchette VS; Fischer K; Björkman S; Oh M; Fritsch S; Schroth P; Spotts G; Astermark J; Ewenstein B;
J Thromb Haemost; 2009 Mar; 7(3):413-20. PubMed ID: 19143924
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country.
Borhany M; Arshad A; Qureshi H; Nadeem R; Jamal A; Ahmed Khan R
Clin Appl Thromb Hemost; 2024; 30():10760296231224357. PubMed ID: 38166474
[TBL] [Abstract][Full Text] [Related]
16. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
17. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
[TBL] [Abstract][Full Text] [Related]
18. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
[TBL] [Abstract][Full Text] [Related]
19. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII therapy for hemophilia A: current and future issues.
Aledort L; Ljung R; Mann K; Pipe S
Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
